ST-148 (antiviral)

ST-148 (antiviral)
Identifiers
	IUPAC name 3-Amino-N-(5-phenyl-1,3,4-thiadiazol-2-yl)-6,7,8,9-tetrahydro-5H-cyclohepta[b]thieno[3,2-e]pyridine-2-carboxamide;
CAS Number	400863-77-6;
PubChem CID	2909914;
ChemSpider	2183647;
ChEMBL	ChEMBL4516506;
Chemical and physical data
Formula	C21H19N5OS2
Molar mass	421.54 g·mol−1
3D model (JSmol)	Interactive image;
	SMILES C1CCC2=CC3=C(N=C2CC1)SC(=C3N)C(=O)NC4=NN=C(S4)C5=CC=CC=C5;
	InChI InChI=1S/C21H19N5OS2/c22-16-14-11-13-9-5-2-6-10-15(13)23-20(14)28-17(16)18(27)24-21-26-25-19(29-21)12-7-3-1-4-8-12/h1,3-4,7-8,11H,2,5-6,9-10,22H2,(H,24,26,27); Key:FGRXYHXHXBKKAK-UHFFFAOYSA-N;

ST-148 is an antiviral drug which acts as a capsid inhibitor. It was developed for treatment of dengue fever, but while it shows strongest activity against dengue virus it also shows broad spectrum activity against other flaviviruses such as Zika virus. It is thought to cause viral capsid proteins to become more rigid, inhibiting both assembly and disassembly of capsids and thereby hindering viral replication and infection of cells.^[1]^[2]^[3]^[4]^[5]

References

^ Touret F, Baronti C, Goethals O, Van Loock M, de Lamballerie X, Querat G (August 2019). "Phylogenetically based establishment of a dengue virus panel, representing all available genotypes, as a tool in dengue drug discovery". Antiviral Research. 168: 109–113. doi:10.1016/j.antiviral.2019.05.005. PMID 31085207.
^ Moshiri J, Constant DA, Liu B, Mateo R, Kearnes S, Novick P, et al. (November 2020). "A Targeted Computational Screen of the SWEETLEAD Database Reveals FDA-Approved Compounds with Anti-Dengue Viral Activity". mBio. 11 (6). doi:10.1128/mBio.02839-20. PMC 7667029. PMID 33173007.
^ Kumar S, Bhardwaj VK, Singh R, Das P, Purohit R (May 2022). "Identification of acridinedione scaffolds as potential inhibitor of DENV-2 C protein: An in silico strategy to combat dengue". Journal of Cellular Biochemistry. 123 (5): 935–946. doi:10.1002/jcb.30237. PMID 35315127.
^ Byrd CM, Dai D, Grosenbach DW, Berhanu A, Jones KF, Cardwell KB, et al. (January 2013). "A novel inhibitor of dengue virus replication that targets the capsid protein". Antimicrobial Agents and Chemotherapy. 57 (1): 15–25. doi:10.1128/AAC.01429-12. PMC 3535982. PMID 23070172.
^ Scaturro P, Trist IM, Paul D, Kumar A, Acosta EG, Byrd CM, et al. (October 2014). "Characterization of the mode of action of a potent dengue virus capsid inhibitor". Journal of Virology. 88 (19): 11540–11555. doi:10.1128/JVI.01745-14. PMC 4178822. PMID 25056895.

[1] Touret F, Baronti C, Goethals O, Van Loock M, de Lamballerie X, Querat G (August 2019). "Phylogenetically based establishment of a dengue virus panel, representing all available genotypes, as a tool in dengue drug discovery". Antiviral Research. 168: 109–113. doi:10.1016/j.antiviral.2019.05.005. PMID 31085207.

[2] Moshiri J, Constant DA, Liu B, Mateo R, Kearnes S, Novick P, et al. (November 2020). "A Targeted Computational Screen of the SWEETLEAD Database Reveals FDA-Approved Compounds with Anti-Dengue Viral Activity". mBio. 11 (6). doi:10.1128/mBio.02839-20. PMC 7667029. PMID 33173007.

[3] Kumar S, Bhardwaj VK, Singh R, Das P, Purohit R (May 2022). "Identification of acridinedione scaffolds as potential inhibitor of DENV-2 C protein: An in silico strategy to combat dengue". Journal of Cellular Biochemistry. 123 (5): 935–946. doi:10.1002/jcb.30237. PMID 35315127.

[4] Byrd CM, Dai D, Grosenbach DW, Berhanu A, Jones KF, Cardwell KB, et al. (January 2013). "A novel inhibitor of dengue virus replication that targets the capsid protein". Antimicrobial Agents and Chemotherapy. 57 (1): 15–25. doi:10.1128/AAC.01429-12. PMC 3535982. PMID 23070172.

[5] Scaturro P, Trist IM, Paul D, Kumar A, Acosta EG, Byrd CM, et al. (October 2014). "Characterization of the mode of action of a potent dengue virus capsid inhibitor". Journal of Virology. 88 (19): 11540–11555. doi:10.1128/JVI.01745-14. PMC 4178822. PMID 25056895.

[1]

[2]

[3]

[4]

[5]